Amalgamated Financial’s Aldeyra Therapeutics ALDX Stock Holding History

Amalgamated Financial’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$35K	Buy	+7,928	New	+$31.6K	﹤0.01%	2565

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

TLP

Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Amalgamated Financial's ALDX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Aldeyra Therapeutics (ALDX) in Q1 2022: 7,928 shares worth $35K. The stake represents ﹤0.01% of the portfolio and ranks #2565 among its holdings.

111 funds tracked by Wall St. Rank hold ALDX as of Q1 2022.

Amalgamated Financial held 7,928 shares of Aldeyra Therapeutics worth $35K as of Q1 2022.
Aldeyra Therapeutics was a new Amalgamated Financial position in Q1 2022.
Aldeyra Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2565 holding.
111 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.